
- Pharmaceutical Executive-12-01-2001
- Volume 0
- Issue 0
Genetic Test Results Off Limits-For Now
London, UK-Insurance companies will be unable to use genetic test results to approve or deny claims for at least the next five years, following a new agreement between the British government and the Association of British Insurers. The move ensures that people can still get insurance coverage whether or not they have had a test.
London, UK-Insurance companies will be unable to use genetic test results to approve or deny claims for at least the next five years, following a new agreement between the British government and the Association of British Insurers. The move ensures that people can still get insurance coverage whether or not they have had a test.
During the next five years, the government will work with the insurance industry to develop a long-term policy. For now, the rules apply to life policies of up to £500,000 and long-term care insurance and income protection of up to £300,000.
Health minister Lord Philip Hunt says, "I recognize that there is public anxiety around the use of genetic test results and insurance, and I welcome this five-year breathing space to work with the industry to get things right. However, if there is evidence of serious and persistent noncompliance by the insurance industry, then the government is prepared to enforce the moratorium, through legislation, if necessary."
Articles in this issue
about 24 years ago
States Target DTC Advertisingabout 24 years ago
Transparent Momentabout 24 years ago
IFPMA Disputes Doctors Without Boarders Reportabout 24 years ago
GSK at Odds with Activistsabout 24 years ago
Protecting People Everywhereabout 24 years ago
Opening the Door to Japanabout 24 years ago
Trade Pact Weakens Patent Protectionsabout 24 years ago
EC Questions Dual Pricingabout 24 years ago
Precious Plasmaabout 24 years ago
FDA Revs Up Counter-Terrorism ActivitiesNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.





